Login In
Psychiatry Drug Alerts​​

In this month's issue...​

  • Quetiapine/Venlafaxine Interaction
  • Lamotrigine Immune System Reaction
  • Safety of Clozapine Rechallenge
  • Clozapine and All-Cause Mortality
  • Aripiprazole–Sertraline in Resistant Depression
  • Mazindol for Adult ADHD
  • Lofexidine for Opioid Withdrawal Symptoms
  • Cardiovascular Safety of Antismoking Agents
  • Brexpiprazole Versus Lurasidone

Child & Adolescent Psychiatry Alerts

In this month's issue...

  • Saffron Extract for Anxiety and Depression
  • Marijuana Legalization and Adolescent Health
  • Treating Anxiety in Emerging Adulthood
  • Pediatric Asenapine
  • Aripiprazole vs Quetiapine: QT Effects

Psychiatry Alerts NOS​​​

In this month's issue...

  • Suicidal Ideation as Specific rTMS Target
  • Deep Brain Stimulation for Depression
  • Dementia Risk After ECT
  • Preventive Cognitive Therapy and Depression Relapse
  • Depression, Anxiety, and Thyroid Disease

​​Primary Care Drug Alerts​​​

In this month's issue​...
  • Erenumab for Migraine Prevention
  • DPP-4 Inhibitors and IBD
  • Legal Marijuana and Adolescent Health
  • Mazindol for Adult ADHD
  • Lamotrigine Immune System Reaction
  • Lofexidine for Opioid Withdrawal

MJ Powers & Co publishes monthly newsletters about the efficacy and safety of drugs and therapeutics. The Alerts contain summaries, from a wide variety of journals, that can help you solve a problem, warn you about safety, or reassure you about efficacy. Not only will you receive the latest research findings, but also useful tools to help you judge research quality, evaluate study independence, and guide you with statistics. 

The Alerts Newsletters are timely and thorough, and you can be assured of objectivity because MJ Powers & Co is independent. There is no sponsorship associated with any of our newsletters, and we accept no advertising. In addition, as a subscriber you will be eligible to enroll in our CME program, which your colleagues consistently rate as "excellent" and "practice changing".